Delivery Vehicles for Self-amplifying RNA

Bathula, Nuthan Vikas; Popova, Petya; Blakney, Anna K.

doi:10.1007/978-3-031-08415-7_16

Cited by 6 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method of vaccination provides a gateway to present complex antigenic composition to the immune system that may include T- and B-cell epitopes [ 22 , 72 ]. For testing the efficacy of these vaccines, several recombinant protein formats have been tested that are conceptually similar and undergo the introduction of HSV ORFs (complete or near complete), into bacterial or other vector systems [ 54 , 73 ].…”

Section: Resultsmentioning

confidence: 99%

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Malik¹,

Sah

Ahsan

et al. 2023

Vaccines

View full text Add to dashboard Cite

Herpes simplex virus (HSV) is a great concern of the global health community due to its linked infection of inconspicuous nature and resultant serious medical consequences. Seropositive patients may develop ocular disease or genital herpes as characteristic infectious outcomes. Moreover, the infectious nature of HSV is so complex that the available therapeutic options have been modified in certain ways to cure it. However, no permanent and highly effective cure has been discovered. This review generates insights into the available prophylactic and therapeutic interventions against HSV. A methodological research approach is used for study design and data complication. Only the latest data from publications are acquired to shed light on updated therapeutic approaches. These studies indicate that the current antiviral therapeutics can suppress the symptoms and control viral transmission up to a certain level, but cannot eradicate the natural HSV infection and latency outcomes. Most trials that have entered the clinical phase are made part of this review to understand what is new within the field. Some vaccination approaches are also discussed. Moreover, some novel therapeutic options that are currently in research annals are given due consideration for future development. The data can enable the scientific community to direct their efforts to fill the gaps that remain unfilled in terms of therapies for HSV. The need is to integrate scientific efforts to produce a proper cure against HSV to control the virus spread, resistance, and mutation in future disease management.

show abstract

Section: Resultsmentioning

confidence: 99%

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Malik¹,

Sah

Ahsan

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…These RNAs based technology has already shown its targeted efficiency in various diseases in terms of high specificity, efficiency, low toxicity, and ease of formulation [83] , [84] . A diverse range of in silico experiments are in research annals for RNA-based inhibitor therapies against influenza virus infection, the need is to dictate these proposed candidates into clinical trials [85] , [86] .…”

Section: Modern Therapeutic Strategies Against Chronic and Seasonal I...mentioning

confidence: 99%

Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review

Malik,

Asghar,

Waheed

2024

Vaccine: X

View full text Add to dashboard Cite

“…However, there are some issues associated with these immunologic preparations such as the need for long-term infusion and hospitalized supervision, high column dosages with the potential risk of excessive immune responses, and bloodborne pathogen development [ 54 , 79 ]. Similarly, they often make it impossible to apply other birth-associated vaccination drives such as against measles/mumps/rubella (MMR) vaccine or the smallpox vaccine [ 20 , 21 , 80 ]. Moreover, the issues of high cost and difficulty of manufacturing are also some issues challenges that need to be overcome for more profound immunoregulatory prophylaxis against RSV infection [ 20 , 21 ].…”

Section: Main Bodymentioning

confidence: 99%

“… Antiviral and Therapeutics Approach Candidates under Clinical Trials References 1. Viral cellular entity inhibitors Aptamers (nucleolin-binding agents) (G)-rich oligonucleotide (nucleolin inhibitor) [ 5 , 6 , 30 , 31 , 56 , 62 , 63 , 80 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 ] 2. Host virus fusion inhibitors GS-5806 (presatovir) VP-14637 (renamed to MDT-637and JNJ-2408068) ALX-0171 [ 9 , 11 , 23 , 29 , 48 , 70 , 100 , 103 , 104 , 105 , 106 , 107 ] 3.…”

Section: Main Bodymentioning

confidence: 99%

Respiratory Syncytial Virus Infection: Treatments and Clinical Management

Malik¹,

Ahmad

Muhammad

et al. 2023

Vaccines

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-compromised individuals and infants below 5 years of age. Worldwide, it is known to be associated with incidences of morbidity and mortality in infants. Despite the seriousness of the issue and continuous rigorous scientific efforts, no approved vaccine or available drug is fully effective against RSV. The purpose of this review article is to provide insights into the past and ongoing efforts for securing effective vaccines and therapeutics against RSV. The readers will be able to confer the mechanism of existing therapies and the loopholes that need to be overcome for future therapeutic development against RSV. A methodological approach was applied to collect the latest data and updated results regarding therapeutics and vaccine development against RSV. We outline the latest throughput vaccination technologies and prophylactic development efforts linked with RSV. A range of vaccination approaches with the already available vaccine (with limited use) and those undergoing trials are included. Moreover, important drug regimens used alone or in conjugation with adjuvants or vaccines are also briefly discussed. After reading this article, the audience will be able to understand the current standing of clinical management in the form of the vaccine, prophylactic, and therapeutic candidates against RSV. An understanding of the biological behavior acting as a reason behind the lack of effective therapeutics against RSV will also be developed. The literature indicates a need to overcome the limitations attached to RSV clinical management, drugs, and vaccine development that could be explained by dealing with the challenges of current study designs with continuous improvement and further work and approval on novel therapeutic applications.

show abstract

Delivery Vehicles for Self-amplifying RNA

Cited by 6 publications

References 62 publications

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review

Respiratory Syncytial Virus Infection: Treatments and Clinical Management

Contact Info

Product

Resources

About